glucovance has been researched along with Diabetes Mellitus, Type 2 in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (72.73) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Boone, K; Ezike, T; Omizu, B; Omoaghe, A; Oyesola, O | 1 |
| Chen, L; Huang, J; Huang, X; Li, X | 1 |
| Bazán-Soto, TB; Castelán-Martínez, OD; Cruz, M; Hoyo-Vadillo, C; Tesoro-Cruz, E; Valladares-Salgado, A | 1 |
| Barkin, JA; Block, HM; Mendez, PE | 1 |
| Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A | 1 |
| Ballas, J; Moore, TR; Ramos, GA | 1 |
| Bokhari, SU; Duckworth, WC; Gopal, UM | 1 |
| Brown, JB; Nichols, GA | 1 |
| Allavoine, T; Howlett, H; Kuhn, T; Nicholson, G; Porte, F | 1 |
| Scheen, AJ | 1 |
| Bruce, S; Dailey, GE; Fiedorek, FT; Noor, MA; Park, JS | 1 |
| Abrahamson, MJ | 1 |
| Blonde, L; Henry, D; Howlett, H; Joyal, S | 1 |
| Davidson, JA; Howlett, HC; Scheen, AJ | 1 |
| Bruce, S; Fiedorek, FT; Howlett, HC; Park, JS | 1 |
| Cadenas, J; Facta, AD; Hsueh, WA; Prior, JO; Quinones, MJ; Schelbert, HR; Schindler, TH | 1 |
| Chang, CT; Chien, HH; Chu, NF; Hsieh, SH; Huang, YY; Lee, IT; Lee, WJ; Sheu, WH; Tang, YJ | 1 |
| Adler, Y; Behar, S; Benderly, M; Boyko, V; Fisman, EZ; Friedensohn, A; Kohanovski, M; Motro, M; Rotzak, R; Schneider, H; Tenenbaum , A | 1 |
| Blonde, L; Sandberg, MI | 1 |
| Hayes, JD; Marchione, V; Mayes, K; Milgram, L; Roselli, A; Seidner, R; Snyder, CM; Stiernberg, CM | 1 |
| Seymour, A | 1 |
4 review(s) available for glucovance and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Management of diabetes in pregnancy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Mass Screening; Metformin; Practice Guidelines as Topic; Pregnancy; Pregnancy in Diabetics; Pregnancy Outcome | 2012 |
[Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease].
Topics: Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Patient Compliance; Periodicity | 2003 |
Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus.
Topics: Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Glyburide; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Lipids; Metformin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Tablets; Time Factors; Treatment Outcome | 2004 |
Glyburide/metformin HCl clinical overview.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Glyburide; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Metformin; United States | 2001 |
6 trial(s) available for glucovance and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions.
Topics: Cross-Over Studies; Diabetes Mellitus, Type 2; East Asian People; Fasting; Glyburide; Humans; Metformin; Tablets; Therapeutic Equivalency | 2023 |
Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Glyburide; Hemoglobin A; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin | 2003 |
Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones | 2004 |
Durable efficacy of metformin/glibenclamide combination tablets (Glucovance) during 52 weeks of open-label treatment in type 2 diabetic patients with hyperglycaemia despite previous sulphonylurea monotherapy.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Treatment Outcome | 2004 |
Beta-cell response to metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Glucose Tolerance Test; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Tablets; Treatment Outcome | 2006 |
Effect of glyburide-metformin combination tablet in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Compliance | 2007 |
12 other study(ies) available for glucovance and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of Combined
Topics: Animals; Aryldialkylphosphatase; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Garcinia kola; Glyburide; Hypoglycemic Agents; Insulin; Male; Metformin; Niacinamide; Plant Extracts; Rats; Rats, Wistar; Streptozocin | 2022 |
CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cross-Sectional Studies; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Female; Genetic Variation; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Logistic Models; Male; Metformin; Mexico; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Time Factors; Treatment Outcome | 2018 |
Octreotide: a novel therapy for refractory sulfonylurea-induced hypoglycemia.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Octreotide | 2013 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Morbidity; Myocardial Infarction; Piperidines; Registries; Retrospective Studies; Risk Factors; Stroke; Sulfonylurea Compounds; Tolbutamide | 2015 |
Slow response to loss of glycemic control in type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Disease Management; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Health Maintenance Organizations; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Northwestern United States; Registries; Retrospective Studies; United States | 2003 |
The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Glyburide; Humans; Hypoglycemic Agents; Metformin; Tablets | 2003 |
Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context.
Topics: Antihypertensive Agents; Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Drug Therapy, Combination; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Piperidines; Postprandial Period | 2004 |
Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Case-Control Studies; Coronary Circulation; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburide; Heart Rate; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2007 |
Glyburide/metformin (Glucovance) for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Glyburide; Hypoglycemic Agents; Metformin | 2000 |
Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.
Topics: Administration, Oral; Coronary Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Survival Analysis; Time Factors | 2001 |
Transitioning patients with type 2 diabetes to a fixed combination > glyburide/metformin tablet.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Glyburide; Humans; Hypoglycemic Agents; Metformin; Tablets | 2000 |
Roundtable. Blueprint for conversion of patients on metformin and sulfonylurea to Glucovance.
Topics: Counseling; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemic Agents; Metformin; Patient Compliance; Patient Education as Topic; Sulfonylurea Compounds; United States | 2001 |